tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks 50 IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

MTVA Stock Latest News

MetaVia Initiates Phase 1 Trial for Obesity Drug
Company AnnouncementsMetaVia Initiates Phase 1 Trial for Obesity Drug
16d ago
8K
MTVA
MetaVia doses first patient in 48 mg MAD cohort of its Phase 1 trial
PremiumThe Fly
MetaVia doses first patient in 48 mg MAD cohort of its Phase 1 trial
16d ago
MTVA
MetaVia files to sell 14.08M shares of common stock for holders
PremiumThe Fly
MetaVia files to sell 14.08M shares of common stock for holders
23d ago
MTVA
MetaVia Holds Virtual Annual Stockholders Meeting
PremiumCompany Announcements
MetaVia Holds Virtual Annual Stockholders Meeting
25d ago
8K
MTVA
MetaVia announces presentation of pre-clinical data on DA-1241
PremiumThe Fly
MetaVia announces presentation of pre-clinical data on DA-1241
1M ago
MTVA
MetaVia Faces Nasdaq Delisting Notice for Low Stock Price
PremiumCompany AnnouncementsMetaVia Faces Nasdaq Delisting Notice for Low Stock Price
2M ago
8K
MTVA
MetaVia Reports Progress in Obesity and MASH Treatments
Premium
Company Announcements
MetaVia Reports Progress in Obesity and MASH Treatments
2M ago
MTVA
MetaVia Updates Corporate Presentation on DA-1726 Progress
Premium
Company Announcements
MetaVia Updates Corporate Presentation on DA-1726 Progress
2M ago
8K
MTVA
MetaVia price target lowered to $3 from $6 at Maxim
PremiumThe Fly
MetaVia price target lowered to $3 from $6 at Maxim
2M ago
MTVA
MetaVia Completes $10 Million Private Placement
PremiumCompany Announcements
MetaVia Completes $10 Million Private Placement
2M ago
8K
MTVA
MetaVia announces $10M private placement
PremiumThe Fly
MetaVia announces $10M private placement
3M ago
MTVA
MetaVia Unveils Promising DA-1241 Trial Results
PremiumCompany Announcements
MetaVia Unveils Promising DA-1241 Trial Results
3M ago
8K
MTVA
MetaVia announces data from DA-1241 trial at EASL
PremiumThe FlyMetaVia announces data from DA-1241 trial at EASL
3M ago
MTVA
MetaVia’s Promising Clinical Trial Results and Future Prospects Drive Buy Rating
Premium
Ratings
MetaVia’s Promising Clinical Trial Results and Future Prospects Drive Buy Rating
3M ago
MTVA
MetaVia Reports Positive Phase 1 Trial Results
Premium
Company Announcements
MetaVia Reports Positive Phase 1 Trial Results
3M ago
8K
MTVA
MetaVia’s DA-1726 obesity candidate shows efficacy in Part 2 of Phase 1 study
PremiumThe Fly
MetaVia’s DA-1726 obesity candidate shows efficacy in Part 2 of Phase 1 study
3M ago
MTVA
MetaVia’s DA-1726: Promising Weight Loss Solution with Strong Buy Potential Despite Market Overreaction
PremiumRatings
MetaVia’s DA-1726: Promising Weight Loss Solution with Strong Buy Potential Despite Market Overreaction
3M ago
MTVA
Promising Clinical Trial Results for MetaVia’s DA-1726: A Potential Leading Weight Loss Therapy
PremiumRatings
Promising Clinical Trial Results for MetaVia’s DA-1726: A Potential Leading Weight Loss Therapy
3M ago
MTVA
MetaVia Announces Positive Phase 1 Trial Results
PremiumCompany Announcements
MetaVia Announces Positive Phase 1 Trial Results
3M ago
8K
MTVA
MetaVia announces ‘positive’ results from Part 2 of Phase 1 trial of DA-1726
PremiumThe FlyMetaVia announces ‘positive’ results from Part 2 of Phase 1 trial of DA-1726
3M ago
MTVA
Positive Outlook on MetaVia’s Promising Pipeline and Strategic Growth Despite Market Challenges
Premium
Ratings
Positive Outlook on MetaVia’s Promising Pipeline and Strategic Growth Despite Market Challenges
4M ago
MTVA
MetaVia Inc. Reports Progress in Cardiometabolic Drug Development
Premium
Company Announcements
MetaVia Inc. Reports Progress in Cardiometabolic Drug Development
4M ago
MTVA

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >